# Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

Study · id `cardio:ct-nct06240403` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06240403](<https://clinicaltrials.gov/study/NCT06240403>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06240403

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06240403. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-01 (anticipated); primary completion 2028-08-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06240403, source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)
- Planned start: 2025-09-01 (anticipated) (ClinicalTrials.gov record NCT06240403, source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)
- Primary completion: 2028-08-28 (anticipated) (ClinicalTrials.gov record NCT06240403, source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)
- Completion: 2029-08-28 (anticipated) (ClinicalTrials.gov record NCT06240403, source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT06240403, source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06240403-2024-12-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
- Condition: Heart Failure, Systolic
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Digoxin 0.125 MG
- Lead sponsor: University of Leeds
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Leeds (`cardio:org-university-of-leeds`)

## Provenance

Content hash: 10c0f0edbbea61dd6da9421d37d328086b6c6dcd96f3fbc133068a6794135aa8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
